Abstract：Objective To explore and analyze the clinical effect of Calcium Dibutyryladenosine Cyclophosphate combined with Salvianolate in acute myocardial infarction.Methods A total of 100 patients with acute myocardial infarction in our hospital from April 2016 to December 2017 were selected as experimental subjects and divided into two groups according to the treatment methods,50 cases in each group.The patients in the control group were treated with conventional treatment,and the patients in the observation group were treated with Calcium Dibutyryladenosine Cyclophosphate combined with Salvianolate.The heart function index level,GRACE coronary heart disease risk score,NIHSS heart function level and adverse event incidence were compared between the two groups.Results The total incidence of adverse events in the observation group(2.00%)was lower than that in the control group(24.00%),and the difference was statistically significant(P＜0.05).After treatment,the proportion of NYHA cardiac function gradeⅠandⅡ in the observation group were significantly higher than those in the control group,while the proportion ofⅢandⅣgrade were lower than those in the control group,and the differences were statistically significant(P＜0.05).After treatment,the LVEDD([48.51±2.37]mm)and LVESD([30.53±1.74]mm)in the observation group were lower than those in the control group([55.46±1.61],[42.94±1.52]mm),while the LVEF([56.52±5.74]%)in the observation group was higher than that in the control group([43.37±1.26]%),and the differences were statistically significant(P＜0.05).After treatment,the GRACE coronary heart disease risk score in the observation group was(70.65±6.11)points,which was lower than that in the control group of(76.52±7.52)points,and the difference was statistically significant(P＜0.05).Conclusion The treatment of patients with acute myocardial infarction with Calcium Dibutyryladenosine Cyclophosphate combined Salvianolate is effective and safe.
京公网安备 11010502046607号